Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2010

Matsubara Daisuke, Ishikawa Shumpei, Oguni Sachiko, Aburatani Hiroyuki, Fukayama Masashi, Niki Toshiro

Abstract excerpt

BACKGROUND: No comprehensive data are available on the molecular predictors of sensitivity to MET inhibitor in lung carcinomas. METHODS: We examined the efficacy of the MET inhibitor PHA665752 in 41 cell lines of non-small lung carcinoma to determine whether sensitivity to the MET inhibitor is correlated with the (1) genetic statuses of MET, epidermal growth factor receptor (EGFR), human epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelial-Mesenchymal Transition
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Receptors, Growth Factor

Share to Sulfones

Source

Identifiers

PMID: 20736805
DOI: 10.1097/JTO.0b013e3181e2a409

Genes

MET
KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.PMID 20736805Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.Semantic proximity Read ↗

MET Activation in Lung Cancer and Response to Targeted TherapiesSemantic proximity Read ↗

Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibitionSemantic proximity Read ↗

MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study.Semantic proximity Read ↗

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and SurvivalSemantic proximity Read ↗

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-rasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.